CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Eloxx Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Eloxx Pharmaceuticals Inc
480 ARSENAL WAY, SUITE 130
Phone: (781) 577-5300p:781 577-5300 WATERTOWN, MA  02472  United States Ticker: ELOXELOX

Business Summary
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director SumitAggarwal 51 4/1/2021 4/1/2021
Interim Chief Financial Officer Daniel E.Geffken 66 1/1/2022 4/1/2021
Independent Director LindsayAndroski 46 7/1/2022 7/1/2022
Independent Director StevenRubin 62 5/16/2014 5/16/2014
Independent Director Alan E.Walts 63 4/1/2021 4/1/2021

Subsidiaries
Business Name Address City State/Province Country
Macrolide Pharmaceuticals, Inc. 480 Arsenal Way Watertown MA United States

Business Names
Business Name
ELOX
Eloxx Pharmaceuticals Ltd.
SVON
SVOND
Zikani Therapeutics, Inc.

General Information
Number of Employees: 18 (As of 12/31/2022)
Outstanding Shares: 3,143,390 (As of 11/9/2023)
Shareholders: 90
Stock Exchange: OTC
Federal Tax Id: 841368850
Fax Number: (302) 636-5454
Email Address: edenkensohn@lhai.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024